Dapagliflozin Slows T2D Onset in Heart Failure Patients |
Journal Updates
eMediNexus Coverage from: 
Dapagliflozin Slows T2D Onset in Heart Failure Patients

0 Read Comments                

Treatment of patients with heart failure but without diabetes with dapagliflozin led to a reduction in the relative incidence of new-onset diabetes over a median follow-up of 18 months in a prespecified analysis from the DAPA-HF trial that included 2,605 heart failure patients without diabetes at baseline.

During the follow-up period, 7.1% of patients in the placebo arm developed type 2 diabetes, compared to 4.9% of those receiving dapagliflozin, representing a 2.2% absolute difference and a 32% relative risk reduction that was statistically significant. The findings were presented at the virtual annual scientific sessions of the American Diabetes Association… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now